CML Publications from Asia

• Occurrence of existing BCR-ABL baseline mutations and associated haplotype (NmR) among chronic myeloid leukemia patients with diverse imatinib response: A Hospital-based study from North-East India
  Hazarika G et al. Biochem Genet, February 2024 (epub ahead of print)
• Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia
  He S et al. Pharm Res, Sept 2023 (epub ahead of print)
• Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution
  Chethan R et al. Ann Hematol, June 2023 (epub ahead of print)
• Long-term outcomes of frontline imatinib therapy for CML in China
  Cheng F et al. Front Oncol, May 2023 – open access publication
• Feasibility of treatment-free remission with generic imatinib:
  Results of generic imatinib-free trial-in-chronic myeloid leukemia-chronic phase study
  Goni D et al. Indian J Med Res, January 2023 - open access publication
  

• Efficacy of flumatinib in CML patients with F359V/C mutation
  Gao H et al. Indian J Hematol Transfus, Apr 2023
• Response to Tyrosine Kinase Inhibitors in Patients with BCR-ABL1 Positive Chronic Myeloid Leukemia; 13.5 Years’ Experience at Patan Hospital, Nepal
  Adhikari A. et al. Blood Res. Rev. March 2023 – open access publication
  
• Effect of imatinib treatment on renal anaemia in chronic myeloid leukemia patients
  Singh AK et al. J Oncol Pharm Pract, March 2023 (epub ahead of print)
• Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India
  Ahmed R et al. Clin Lymphoma Myeloma Leuk, February 2023
• Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects
  Wang Y et al. Expert Opin Investig Drug, February 2023 (epub ahead of print)
• Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca2+-dependent gap junction intercellular communication
  Liu X et al. Chin Med J (Engl.), February 2023 (epub ahead of print) – open access publication
  
• Supplemental pioglitazone to patients of CML with suboptimal TKI response: A pragmatic pilot study
  Yanamandra U et al. Indian J Hematol Blood Transfus, January 2023
• OCT-1 expression in patients with chronic myeloid leukemia: A comparative analysis with respect to imatinib treatment
  Bozhurt Bulakci B et al. Indian J Hematol Blood Transfus, Oct 2023
• Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia
  Cheng F et al. Cancer, Oct 2022 (epub ahead of print)
• Efficacy and safety of generic dasatinib in patients with newly diagnosed chronic myeloid leukemia in chronic-phase: A multicentre prospective study in China
  Yu W et al. Clin Lymphoma Myeloma Leuk, September 2022
• Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study
  Dey S et al. Cancer Treat Res Commun, September 2022 (epub ahead of print)
  – open access publication
• Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
  Ghosh K. J Postgrad Med, April – June 2022
• Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloid leukemia patients from Pakistan
  Mukry SN et al. BMC Cancer – open access publication
• Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review
  Zhang Y et al. J Comp Eff Res, April 2022 (epub ahead of print)
• Challenges in access to new therapeutic agents: Marginalised patients with cancer in Pakistan and the need for new guidelines
  Aziz Z et al. JCO Glob Oncol, February 2022 – open access publication
  
• Long-term outcome of Philadelphia chromosome positive leukemia from Eastern Indian Subcontinent: An experience in the era of tyrosine kinase inhibitor (TKI) therapy
  Dey S et al. Clin Lymphoma Myeloma Leuk, November 2021
• Cytogenetic abnormalities in patients with haematological malignancies in Lahore city, Pakistan
  Awan UA et al. Braz J Biol, October 2021 – open access publicatio
• Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to imatinib among CML patients in Kashimir
  Baba SM et al. Int J Lab Hematol, October 2021
• Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China
  Maheshwari VK et al. PLoS One, October 2021 – open access publication
• Health-related quality of life using EQ-5D among chronic myeloid leukemia patients in health centres in Klang Valley, Malaysia
  Wan Puteh SE et al. PLoS, August 2021 – open access publication
• Long-term outcome of tyrosine kinase treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic-phase
  Zheng YZ et al. Chin Med J (Engl), July 2021 - open access publication
• Therapeutic effect of imatinib made in real world to newly diagnosed chronic myeloid leukemia
  Zhanggguo Shi Yan Xue Ye Xue Za Zhi, April 2021 (in Chinese)
• Association of DNA repair gene XPC Ala499 Val (rs2228000 C<T) and Lys 939Gin (rs 22280001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case-control study in South Indian population
  Lakkireddy S et al. J Gene Med, April 2021 (epub ahead of print)
• Adherence to tyrosine kinase inhibitors among adult chronic myeloid leukemia patients in a Malaysia hospital
  Lee PM et al. Int J Clin Pharm, February 2021
• Challenges for pediatric hematology oncology in Pakistan during coronavirus pandemic
  Rahat Ul-Ain und Faizan M. Pediatr Blood Cancer, February 2021 – open access publication
  
• Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to imatinib among chronic myeloid leukemia patients in Kashmir
  Baba SM et al. Int J Lab Hematol, January 2021 (epub ahead of print)
• Social and financial barriers to optimum TKI treatment in patients with CML –
  A Knowledge-Attitude-Practices study from India
  Gupta N et al. Mediterr J Hematol Infect Dis, January 2021 – open access publication
  
• Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: Sharing experience of a hemato-oncology center from Eastern India
  Phukan A et al. Ann Hematol, October 2020 (epub ahead of print)
• Distribution of BCR-ABL1 transcript variants in Nigerians with CML
  Owojuyigbe TO et al. Indian J Hematol Blood Transf, October 2020
• Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia
  Shi DY et al. Zhonghua Xue Ye Xue Za Zhi, June 2020 (in Chinese)
  – open access publication
• BCR-ABL gene transcript types of patients with chronic myelogenous leukemia in Yogyakarta, Indonesia
  Paramita DK et al. Asian Pac J Cancer Prev, June 2020
  – open access publication
• Poor tolerability to ponatinib in Indian CML patients
  Singh C et al. Blood Adv, May 2020 – open access publication
• Halving time of BCR-ABL1 in chronic myeloid leukemia: Is it better than day-90 value –
  A multicenter study from South India
  Karpurmath SV et al. Clin Lymphoma Myeloma Leuk, May 2020 - open access publication
• Real-world experience of imatinib in pediatric chronic-phase chronic myeloid leukemia: A Single-center experience from India
  Ganguly S et al. Clin Lymphoma Myeloma Leuk, March 2020 (epub ahead of print)
• Relationship between PANTR1 and imatinib resistance of chronic myeloid leukemia cell line K562 and its related mechanisms
  Gao JJ et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, April 2020 (in Chinese)
• Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
  Yuan T et al. Zhonghua Xue Ye Xue Za Zhi, February 2020 (in Chinese)
• A prognostic and predictive study of BCR-ABL expression based on characterization of fusion transcripts
  Upadhyay V et al. Indian J Clin Biochem, January 2020
• Additional chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia
  Tashfeen S et al. Pak J Med Sci, January – February 2020 – open access publication
• Chronic myeloid leukemia in children: challenges and opportunities: Based on the 7^th Dr. I.C. Verma Excellence Award for young pediatricians delivered as oration on the 29^th Sept 2019
  Bansal D. Indian J Pediatr, February 2020 (epub ahead of print)
• Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China
  Deng M et al. Medicine (Baltimore), February 2020 – open access publication
• Standardization of BCR-ABL1 quantification on the International scale in China using locally developed secondary reference panels
  Zhang JW et al. Exp Hematol, December 2019
• Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics
  Dou XL et al. Zhonggua Xue Ye Xue Za Zhi, November 2019 (in Chinese)
• A comprehensive review of chronic myeloid leukemia. An Indian perspective
  Varma PK et al. J Assoc Genet Technol 2019
• Association between C1236T genetic variant of ABCB1 gene and molecular response to imatinib by Indonesian chronic myeloid patients
  Rinaldi I et al. Asian Pac J Cancer Prev, November 2019
• Impact of additional chromosomal aberrations present at diagnosis on outcome of adolescent and young adult chronic myeloid leukemia patients: A single center experience
  El-Ghammaz AMS et al. Indian J Hematol Blood Transfus, October 2019
• A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia
  Samal P et al. Indian J Cancer, Jul – Sept 2019
• Values of different prognostical score systems for patients with newly diagnosed chronic myeloid leukemia
  Wang PR et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, June 2019 (in Chinese)
• Effect of stably down-regulating FMI expression of K562 cells on sensitivity of K562 cells to imatinib mesylate
  Han YH et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, June 2019 (in Chinese)
• Monitoring and analysis of Chinese chronic myeloid leukemia patients who have stopped tyrosine kinase inhibitor therapy
  Shen N et al. Curr Med Sci, April 2019
• Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India
  Sazawal S et al. South Asian J Cancer, April – June 2019
• Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors therapy
  Yu L et al. Zhonghua Xue Ye Xue Za Zhi, April 2019 (in Chinese)
• Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in imatinib treated CML patients: A study from India
  Sazawal S et al. Indian J Pathol Microbiol, April – June, 2019
• Chronic myeloid leukemia presenting with fleeting facial nerve palsy
  Sandal R et al. Indian J Hematol Blood Transfus, April 2019
• Co-occurrence of t(8;21)(q22;q22) and t(9;22)(q34;q11) in a case with chronic myelogenous leukemia
  Gong J et al. Zhonghua Yi Xue Yi Chaun Xue Za Zhi, March 2019
  (in Chinese)
• Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
  Chen YL et al. Zhonghua Xue Ye Xue Za Zhi, February 2019 (in Chinese)
• Population pharmacokinetic and pharmacogenetics of imatinib in Chinese with chronic myleloid leukemia
  Wang Q et al. Pharmacogenomics, February 2019
  (epub ahead of print)
• Uncontrolled neovascular glaucoma - an alarming manifestation of chronic myeloid leukemia on imatinib therapy: a case report and review of literature
  Roop P et al. Indian J Ophtalmol, February 2019
• Adolescent and young adult chronic myeloid leukemia in real-world settings: Experience from a Tertiary Care Institute in Northern India
  Yanamandra U et al. J Adolesc Young Adult Oncol, February 2019
• A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic-phase
  Zhang LQ et al. Zhongua Er Ke Za Zhi, February 2019 (in Chinese)
• Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China
  Zhu YJ et al. Zhonghua Xue Ye Xie Za Zhi, December 2018 (in Chinese)
• Efficacy and safety of generic dasatinib as a second-line treatment for patients with chronic myeloid leukemia: a multicenter retrospective study in Hubei province
  Chen LF et al. Curr Med Sci, December 2018
• Leukostasis retinopathy: An uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis – a case report and review of the literature
  Chen B et al. Indian J Ophthalmol, December 2018
• Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia
  Costa HZ et al. Hematol Transfus Cell Ther, Oct – Dec 2018
• Adolescent and young adult chronic myeloid leukemia in real-world settings: Experience from a Tertiary Institute in Northern India
  Yanamandra U et al. J Adolesc Young Adult Oncol, November 2018 (epub ahead of print)
• Imatinib-induced igA Pemphigus: Subcorneal pustular dermatosis type
  Sood A et al. Indian Dermatol Online J, Sept-Oct, 2018
• Relationship between BCR-ABL^IS and prognosis and affecting factors for prognosis in CML patients treated with TKI for 12 months
  Hu CY et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, October 2018 (in Chinese)
• Affect of additional chromosomal abnormalities on the outcomes of CML-CP patients receiving TKI therapy
  Yue YH et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, October 2018 (in Chinese)
• Variation in adherence measures to imatinib therapy
  Yanamandra U et al. J Glob Oncol, September 2018
• Geographic hematology: Some observations in Mexico
  Colunga-Pedraza PR et al. Acta Haematol, September 2018 (epub ahead of print)
• Experience with the use of Nilotinib in Indian Patients
  Manuprasad A et al. Indian J Hematol, Blood Transf, July 2018
• Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia
  Zhao HF et al. Zhonghua Xue Ye Xue Za Zhi, July 2018 (in Chinese)
• Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic-phase receiving tyrosine kinase-inhibitor therapy
  Yu L et al. Zhongua Xue Ye Xue Za Zhi, July 2018 (in Chinese)
• Prognostic implications of BCR-ABL fusion transcript variants in chronic myeloid leukemia (CML) treated with imatinib. A first of its kind study on CML patients of Kashmir
  Azad NA et al. Asian Pac J Cancer Prev, June 2018
• Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML Alliance
  Zhang J et al. Blood Cancer J, June 2018
• BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients
  Than H et al. Leuk Lymphoma, June 2018 (epub ahead of print)
• Imatinib as second-line treatment drug for CML patients intolerant to nilotinib
  Qi J et al. Zhangguo Shi Yan Xue Ye Xue Zh Zhi, April 2018 (in Chinese)
• Laboratory monitoring of chronic myeloid leukemia in patients with tyrosine kinase inhibitors
  Chauhan R et al. Indian J Hematol Blood Transfus, April 2018
• The molecular-cytogenetic characterization and tyrosine kinase inhibitors efficacy in newly diagnosed chronic phase CML patients with variant Philadelphia chromosomes
  Zhao JJ et al. Zhanghua Xue Ye Xue Za Zhi, March 2018 (in Chinese)
• Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients
  Vinay K et al. Int J Dermatol, March 2018
• Comparative study of clinic-hematological features, molecular spectrum and response to imatinib in chronic myelogenous patients: Pediatric and adolescents versus adults
  Tahlan A et al. Indian J Hematol Blood Transf, January 2018
• Patient’s and hematologist’s concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
  Jiang Q et al. J Cancer Res Clin Oncol, January 2018 (epub ahead of print)
• The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single center study from China
  Shao H et al. Leuk Lymphoma, January 2018 (epub ahead of print)
• Miro RNA targeted to chronic myeloid leukemia BCR-ABL oncogene screen using deacetylase inhibitor
  Ai ZD et al. Zhonghua Yi Xue Za Zhi, January 2018 (in Chinese)
• Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China
  Li N et al. Clin Drug Investig, January 2018
• BCR-ABL and JAK 2V617F mutation co-existence, rare or just unexplored?
  Darling HS et al. Indian J Hematol Blood Transfus, December 2017
• Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China
  Li N et al. Clin Drug Investig, October 2017 (epub ahead of print)
• The relationship between MDM2 T309G polymorphism and leukemia in the Chinese population: Evidence from a meta-analysis
  Zhao D et al. Clin Lab, October 2017
• PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thromobocytopenic in chronic myeloid leukemia: A study from India
  Guru SA et al. Tumour Biol, October 2017
• Comparison of the applicability of Hasford score and European treatment and outcome study score in Indian patients with chronic phase chronic myeloid leukemia on dasatinib therapy
  Narang NC et al. South Asian J Cancer, July-Sept 2017
• Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
  Jiang Q et al. J Cancer Res Clin Oncol, September 2017 (epub ahead of print)
• Molecular response to imatinib and it’s correlation with mRNA expression levels of imatinib influx transporter (OCT1) in Indian chronic myeloid leukemia patients
  Chhikara S et al. Asian Pac J Cancer Prev, September 2017
• Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms
  Yap E et al. Malays J Pathol, August 2017
• BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil – not so real
  Pagnano KBB, Rev Bras Hematol Hemoter, July – September 2017
• Mutation analysis in chronic myeloid leukemia patients in chronic phase on imatinib having delayed achievement of milestones or loss of response
  Tripathi AK et al. Indian J Hematol Blood Transfus, September 2017 
• Understanding and challenges in taking tyrosine kinase inhibitors among Malaysian chronic myeloid leukemia patients: A qualitative study
  Lim YM et al. Asian Pac J Cancer Prev, July 2017
• Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
  Rev Bras Hematol, July – September 2017
• Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicentre retrospective clinical study
  Jiang H et al. Zhonghua Xue Ye Xue Za Zhi, July 2017 (in Chinese)
• Chronic myeloid leukemia in India
  Ganesan P et al. J Glob Oncol, July 2017
• New genetic variation in BCR gene of major B3a2 breakpoint BCR-ABL fusion gene in patients with chronic myelogenous leukemia in Yogyakarta, Indonesia
  Sholikah TA et al. Asian Pac J Cancer, May 2017 
• Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy
  Jiang Q et al. J Cancer Res Clin Oncol, June 2017
• Evaluation of BCR-ABL gene rearrangement among Bangladeshi chronic myeloid leukemia patients
  Dipta TF et al. Mymensingh Med J, April 2017
• The use of Imatinib resistance mutation analysis to direct therapy in philadelphia chromosome/BCR-ABL1 positive CML patients failing Imatinib treatment in Patan Hospital, Nepal
  Kayastha GK et al. Br J Haematol, May 2017 (epub ahead of print)
• Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India
  Sazawal S et al. Ann Diagn Pathol, April 2017
• Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China
  Jiang Q. J Cancer Res Clin Oncol, July 2016
• Young age and high cost are associated with future performence for stopping tyrosine kinase inhibitor therapy in chinese with chronic myeloid leukemia
  Jiang Q. et al. J Cancer Res Clin Oncol, July 2016
• Effects of Quercetin on chronic myeloid leukemia cell line resistant to imatinib and it’s mechanisms
  Lu HY et al. Zhongguo Shi Yan Xue Ye Xuo Za Zhi, April 2017 (in chinese)
• Research progress of Homoharringtonine effect on IM-resistant chronic myeloid leukemia - review
  Wang Q et al. Zhangguo Shi You Xue Za Zhi, April 2017
• The impact of medical insurance coverage and molecular monitoring frequency and outcomes in chronic myeloid leukemia: real-world evidence in China
  Sheng G et al. J Med Econ, April 2017
• Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis
  Sheng G. et al. J Med Econ, April 2017
• Clinical analysis for 42 imatinib-resistant patients with chronic myelogenous leukemia
  Liu X et al. Zhangguo Shi Yan Xue Ye Xue Xue Za Zhi, April 2017 (in chinese)
• Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec: 10 years experience at Patan Hospital, Nepal
  Kayastha GK et al. Br J Haematol, March 2017
• Role and mechanisms of the interaction of BCR-ABL with E3 ligase c-CBL in targeting therapy of chonic myelogenous leukemia
  Mao JH et al. Zhongguo Shi Yau Xue Ye Xue Za Zhi, February 2017 (in Chinese)
• Establishment and identification of SCL-tTFA/BCR-ABL transgenic mouse model with chronic myeloid leukemia
  Lin Y et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi, February 2017 (in Chinese)
• Analysis of isodentric Ph chromosomes in chronic myeloid leukemia blast crisis
  Li Q et al. Zhongguo Yi Xue Xi Chuan Xuo Za Zhi, February 2017 (in chinese)
• Clinical significance of cytogenetic monitoring in chronic myeloid leukemia
  Pan CY et al. Zhonghua Xue Ye Xue Za Zhi, February 2017 (in chinese)
• Myeloid sarcoma as the first sign of progression of chronic myeloid leukemia in medullary chronic phase: Experience from a tertiary cancer centre in Southern India Department of Medical Oncology, Kidwai 
  Memorial Institute of Oncology, Bengaluru, India. Guld J Oncol, January 2017
• A retrospective study of clinical profile and long-term outcome to imatinib mesylate alone in childhood chronic myeloid leukemia in chronic phase
  Department of medical and pediatric oncology, The Gujarat Cancer and Research Institute in Ahmadabad, Gujarat, India. Gulf J Oncol, January 2017
  Association of genetic polymorphisms of KIR-HLA system with chronic myeloid leukemia among ethics Hans from southern China
  Deng Z et al. Zhonghua Yi Xue Chuan Xue Za Zhi, February 2017 (in chinese)
• Predictive and prognostic implications of variant Philadelphia translocations in CML: Experience from a tertiary Oncology Center in Southern India
  Kanakasettty GB et al. Clin Lymphoma Myeloma Leuk, January 2017
• BCR-ABL transcripts (MR 4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia
  Lee SE et al. Korean J Int Med, January 2017
  Patan hospital experience in treating Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec, the first generation specific tyrosine kinase inhibitor
  Kayastha GK, BMC Blood Disorders, December 2016

{rscomments off}